Abstract
Abstract
Background
Childhood adenoid hypertrophy (AH) is common and is often associated with allergic asthma, resulting in complications like obstructive sleep apnea syndrome (OSAS). Management of the disease and its complications is often challenging.
Case presentation
We report here a case of a 10-year-old boy who suffered from severe allergic asthma and rhinitis and was treated with omalizumab. Before the treatment, the childhood asthma control test (C-ACT, 14), visal analog scale (VAS, 7) and lung function (mild obstructive ventilation dysfunction and moderate to severe dysfunction in ventilation in small airway) were seriously affected. Polysomnography showed OSAS (apnea hypopnea index, AHI, 6.4), low hypooxia saturation (lowest pulse oxygen saturation, LoSpO2, 70%), and adenoid hypertrophy (at grade III). After treating with omalizumab for 4 weeks (once treatment), the ventilation function, symptoms of asthma and allergic rhinitis (C-ACT, 24; VAS, 2), and OSAS (AHI: 1.8 and LoSpO2: 92.6%) were all improved, and the adenoids size was also significantly reduced to grade II. And during the following 3 times of treatment, the allergic symptoms continued improving, and the size of adenoid was reduced to grade I. Even 6.5 months after cessation of omalizumab, the size of adenoid remained at grade I.
Conclusion
This is the first documented case that childhood adenoid hypertrophy can be significantly improved by omalizumab.
Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Insect Science,Ecology,Ecology, Evolution, Behavior and Systematics
Reference12 articles.
1. Xu Z, Wu Y, Tai J, Feng G, Ge W, Zheng L, et al. Risk factors of obstructive sleep apnea syndrome in children. J Otolaryngol Head Neck Surg. 2020;49(1):11.
2. Muhammed FE, Mahmut D, Ahmet AC, Merve IN. Adenoid hypertrophy in children with allergic disease and influential factors. Int J Pediatr Otorhinolaryngol. 2015;79(5):694–7.
3. Global Initiative for Asthma. Global strategy for asthma management and prevention, 2021.[updated 2021; cited 2022 Feb 17]. https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf.
4. Sztafińska A, Jerzyńska J, Stelmach W, Woicka-Kolejwa K, Stelmach I. Quality of life in asthmatic children and their caregivers after two-year treatment with omalizumab, a real-life study. Postepy Dermatol Alergol. 2017;34(5):439–47.
5. Galić MZ, Klančnik M. Adenoid size in children with otitis media with effusion. Acta Clin Croat. 2022;60(3):532–9.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Antiallergics/montelukast;Reactions Weekly;2023-04-29